Spots Global Cancer Trial Database for afatinib
Every month we try and update this database with for afatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC) | NCT01931306 | Carcinoma, Non-... | Afatinib | 18 Years - | Boehringer Ingelheim | |
| Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC | NCT05516589 | Head and Neck S... | Nab-paclitaxel Cisplatin Tislelizumab Afatinib | 18 Years - | West China Hospital | |
| Afatinib Expanded Access Program | NCT01649284 | Carcinoma, Non-... | afatinib | 18 Years - | Boehringer Ingelheim | |
| Trial of Afatinib in Pediatric Tumours | NCT02372006 | Neuroectodermal... Rhabdomyosarcom... | afatinib | 1 Year - 18 Years | Boehringer Ingelheim | |
| Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | NCT02795156 | Non-small Cell ... Urothelial Carc... Gastrointestina... Upper Aerodiges... | Afatinib Regorafenib Cabozantinib | 18 Years - | SCRI Development Innovations, LLC | |
| LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | NCT01345669 | Head and Neck N... | Placebo Afatinib | 18 Years - | Boehringer Ingelheim | |
| Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer | NCT02501603 | Gastric Cancer Gastroesophagea... | afatinib paclitaxel | 19 Years - | Yonsei University | |
| BIBW 2992 (Afatinib) and Vinorelbine | NCT01531764 | Carcinoma Breas... | BIBW 2992 in co... | 18 Years - | University of Magdeburg | |
| Afatinib Osimertinib Sequencing NIS | NCT03370770 | Carcinoma, Non-... | Afatinib Osimertinib | 18 Years - | Boehringer Ingelheim | |
| Maintaining ERBB Blockade in EGFR-mutated Lung Cancer | NCT02488694 | Non-small-cell ... | Afatinib Pemetrexed | 18 Years - | AIO-Studien-gGmbH | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE) | NCT02595840 | Non-small-cell ... | Afatinib Pemetrexed | 18 Years - | Universität Duisburg-Essen | |
| Safety Study of Afatinib for Brain Cancer | NCT02423525 | Brain Cancer | Afatinib | 18 Years - | Saint John's Cancer Institute | |
| Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations | NCT02044380 | Carcinoma, Non-... | Afatinib | 18 Years - | Boehringer Ingelheim | |
| A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel | NCT01251653 | Neoplasms | Afatinib Afatinib docetaxel gemcitabine | 18 Years - | Boehringer Ingelheim | |
| Cambridge Brain Mets Trial 1 | NCT02768337 | Lung Cancer Breast Cancer Brain Cancer Advanced Breast... Advanced Lung C... | Afatinib 2 Gy targeted r... 4 Gy targeted r... | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma | NCT03827070 | Non Small Cell ... | Afatinib Talcum powder | 21 Years - 40 Years | Center Trials & Treatment Europe | |
| Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors) | NCT05107193 | Solid Tumors | afatinib | 18 Years - | Boehringer Ingelheim | |
| GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations | NCT02047903 | Carcinoma, Non-... | Afatinib | 18 Years - | Boehringer Ingelheim | |
| To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation | NCT04132102 | Lung Squamous C... | Afatinib | 18 Years - | Shanghai Chest Hospital | |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | NCT04185883 | Advanced Solid ... Kirsten Rat Sar... | Sotorasib Trametinib RMC-4630 Afatinib Pembrolizumab Panitumumab Carboplatin, pe... Atezolizumab Palbociclib MVASI® (bevaciz... TNO155 IV Chemotherapy... IV Chemotherapy... BI 1701963 AMG 404 Everolimus | 18 Years - 100 Years | Amgen | |
| The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib | NCT04640870 | Non Small Cell ... EGF-R Positive ... EGFR Gene Mutat... | Afatinib | 18 Years - | Hellenic Cooperative Oncology Group | |
| Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib | NCT02511847 | Triple Negative... | Afatinib | 20 Years - | National Taiwan University Hospital | |
| Biomarker-based Study in R/M SCCHN | NCT03088059 | Carcinoma, Squa... | Afatinib Palbociclib standard of car... IPH2201 Durvalumab Niraparib INCAGN01876 | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA | NCT02629523 | Lung Neoplasms EGFR Gene Mutat... | Afatinib | 19 Years - | Chonnam National University Hospital | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | NCT05834348 | Non-Small Cell ... | lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib | 18 Years - 100 Years | Pfizer | |
| Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity | NCT02183883 | Non-small Cell ... | Afatinib | 18 Years - | University College, London | |
| Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA | NCT02629523 | Lung Neoplasms EGFR Gene Mutat... | Afatinib | 19 Years - | Chonnam National University Hospital | |
| To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC | NCT05818982 | Advanced Esopha... | Afatinib Irinotecan | 18 Years - 75 Years | Peking University | |
| Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours | NCT02020577 | Neoplasms | Cetuximab( erbi... Afatinib | 18 Years - | Boehringer Ingelheim | |
| Pilot Trial for Treatment of Recurrent Glioblastoma | NCT05432518 | Glioblastoma Recurrent Disea... Recurrent Gliob... | Afatinib Dasatinib Palbociclib Everolimus Olaparib | 18 Years - | AHS Cancer Control Alberta | |
| Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. | NCT01649271 | Breast Neoplasm... Stomach Neoplas... | Herceptin afatinib trastuzumab Herceptin afatinib afatinib | 18 Years - 99 Years | Boehringer Ingelheim | |
| Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma | NCT05519917 | Chordoma of Cli... | Afatinib | 18 Years - | Huashan Hospital | |
| Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | NCT03711422 | Non-small Cell ... Leptomeningeal ... Central Nervous... | Afatinib Afatinib | 21 Years - | National Cancer Centre, Singapore | |
| Observational Study of Afatinib 30 mg Daily | NCT04909073 | Non-Small Cell ... Epidermal Growt... | Afatinib | 18 Years - 99 Years | National University Hospital, Singapore | |
| Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone | NCT02115048 | Breast Neoplasm... | Letrozole Afatinib | 18 Years - | Translational Research in Oncology | |
| Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification | NCT04880811 | Esophageal Squa... | Afatinib Toripalimab | 18 Years - 70 Years | Peking University | |
| Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma | NCT03827070 | Non Small Cell ... | Afatinib Talcum powder | 21 Years - 40 Years | Center Trials & Treatment Europe | |
| An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) | NCT01853826 | Carcinoma, Non-... | afatinib | 18 Years - | Boehringer Ingelheim | |
| LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung | NCT01466660 | Lung Neoplasms | Afatinib gefitinib | 18 Years - 90 Years | Boehringer Ingelheim | |
| Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer | NCT03727724 | Carcinoma, Non-... | Afatinib Cetuximab | 18 Years - | The Netherlands Cancer Institute | |
| Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC | NCT05516589 | Head and Neck S... | Nab-paclitaxel Cisplatin Tislelizumab Afatinib | 18 Years - | West China Hospital | |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | NCT03785249 | Advanced Cancer Metastatic Canc... Malignant Neopl... | MRTX849 Pembrolizumab Cetuximab Afatinib | 18 Years - | Mirati Therapeutics Inc. | |
| Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | NCT03711422 | Non-small Cell ... Leptomeningeal ... Central Nervous... | Afatinib Afatinib | 21 Years - | National Cancer Centre, Singapore | |
| Safety Study of Afatinib for Brain Cancer | NCT02423525 | Brain Cancer | Afatinib | 18 Years - | Saint John's Cancer Institute | |
| Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | NCT06302621 | Advanced Solid ... Unresectable So... Metastatic Soli... Cholangiocarcin... | Afatinib Pemigatinib | 18 Years - | Massachusetts General Hospital | |
| Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer | NCT03054038 | Non-Small Cell ... | Afatinib Necitumumab Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study | NCT04575415 | NSCLC | Bevacizumab Erlotinib Gefitinib Icotinib Afatinib Dacomitinib Osimertinib | 18 Years - 75 Years | Guangdong Association of Clinical Trials | |
| Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma | NCT03486509 | Squamous Cell C... | Afatinib | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation | NCT01953913 | Carcinoma, Non-... | Afatinib | 18 Years - | Boehringer Ingelheim | |
| Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib) | NCT01880515 | Skin Rash Lung Cancer | Tetracycline | 18 Years - | Instituto Nacional de Cancerologia de Mexico | |
| Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer | NCT01783587 | Squamous Cell C... | Afatinib Docetaxel Radiation Thera... | 18 Years - | Dana-Farber Cancer Institute | |
| Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer | NCT02450656 | Colorectal Neop... Gastrointestina... Pancreatic Neop... Carcinoma, Non-... | Afatinib Selumetinib Docetaxel | 18 Years - | The Netherlands Cancer Institute | |
| Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC | NCT02625168 | Lung Cancer | Afatinib Erlotinib | - | The University of Hong Kong | |
| Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. | NCT02470065 | Non Small Cell ... | Afatinib Immediate surge... | 18 Years - 90 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE) | NCT02595840 | Non-small-cell ... | Afatinib Pemetrexed | 18 Years - | Universität Duisburg-Essen | |
| AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC | NCT04413201 | Non-squamous NS... | Afatinib Osimertinib | 18 Years - | Johannes Gutenberg University Mainz | |
| Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer | NCT05267288 | PFS | afatinib | 18 Years - 85 Years | Qingdao Central Hospital | |
| Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck | NCT02979977 | Squamous Cell C... | cetuximab afatinib | 18 Years - | Yale University | |
| Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung | NCT03157089 | Carcinoma, Non-... | Afatinib pembrolizumab | 18 Years - | Boehringer Ingelheim | |
| The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting | NCT02271906 | Lung Cancer | BIBW 2992 | 18 Years - | M.D. Anderson Cancer Center | |
| Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE) | NCT02595840 | Non-small-cell ... | Afatinib Pemetrexed | 18 Years - | Universität Duisburg-Essen | |
| Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) | NCT02695290 | Carcinoma, Non-... ErbB Receptors | Afatinib | 18 Years - | Boehringer Ingelheim | |
| The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib | NCT04640870 | Non Small Cell ... EGF-R Positive ... EGFR Gene Mutat... | Afatinib | 18 Years - | Hellenic Cooperative Oncology Group | |
| JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy | NCT05164848 | Esophageal Squa... | JMT101 Afatinib | 18 Years - | Peking University | |
| Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma | NCT05519917 | Chordoma of Cli... | Afatinib | 18 Years - | Huashan Hospital | |
| Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | NCT03711422 | Non-small Cell ... Leptomeningeal ... Central Nervous... | Afatinib Afatinib | 21 Years - | National Cancer Centre, Singapore | |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | NCT03785249 | Advanced Cancer Metastatic Canc... Malignant Neopl... | MRTX849 Pembrolizumab Cetuximab Afatinib | 18 Years - | Mirati Therapeutics Inc. | |
| Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | NCT02191891 | Carcinoma, Non-... | BI 836845 afatinib | 18 Years - | Boehringer Ingelheim | |
| LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | NCT01523587 | Carcinoma, Non-... | afatinib erlotinib | 18 Years - | Boehringer Ingelheim | |
| LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | NCT01345682 | Head and Neck N... Carcinoma, Squa... | Afatinib Methotrexate | 18 Years - | Boehringer Ingelheim | |
| Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors | NCT05298176 | Non-Small Cell ... | Afatinib, Osime... | 18 Years - | Amsterdam UMC, location VUmc | |
| Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT03652233 | Recurrent Squam... Metastatic Squa... Squamous Cell C... | Nivolumab Afatinib | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib | NCT04640870 | Non Small Cell ... EGF-R Positive ... EGFR Gene Mutat... | Afatinib | 18 Years - | Hellenic Cooperative Oncology Group | |
| Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction | NCT05865132 | Esophagus Squam... | Palbociclib Afatinib | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer | NCT02716311 | Non Small Cell ... | Afatinib Cetuximab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | NCT02208843 | Carcinoma, Non-... | Afatinib | 18 Years - | Boehringer Ingelheim | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | NCT04183712 | Gallbladder Car... | gemcitabine and... Afatinib | 18 Years - 80 Years | Shanghai Jiao Tong University School of Medicine | |
| Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC) | NCT01931306 | Carcinoma, Non-... | Afatinib | 18 Years - | Boehringer Ingelheim |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
